CSCO guidelines are released

"The annual progress seminar on clinical oncology in China, sponsored by the Chinese Society of Clinical Oncology() was held on the line recently, and experts and scholars summarized the update of the digestive tract oncology guidelines in recent years that have attracted much attention in recent years, and the status of immunotherapy in the new edition of the guidelines has improved compared to the old guidelinesToday, the author on esophageal cancer, stomach cancer, liver cell cancer immunotherapy guidelines update the main points to do a summary for your readers to refer toLate esophageal cancer second-line immunotherapy update point Carelli bead singular recommendation (scale cancer evidence) from the specific update of this edition of the guidelines for the "patient-level expert recommendation program added Carrelli bead ssingles (scale cancer evidence)The recommendation is mainly based on randomized, open, chemotherapy drug control, multicenter phase III clinical research results as the first in China's advanced esophageal scale cancer patients, the largest sample of immunoosmic checkpoint inhibitors study included in the case of first-line chemotherapy failure of advanced or metastatic esophageal scale cancer patients (Carelliju sadromator and chemotherapy group, respectively) received Carrellibead singo-monotherapy (once a week) Once a week) or Iliticon (once a week)The results showed that carellizumab significantly prolonged the median survival of patients (months to months) and nearly increased objective remission rate (yes) longer response duration (months to months) and that patients with esophageal syllin cancer, regardless of expression state, could benefit from chemotherapy compared to chemotherapyThe tolerance of Therlyi Beads is good, safe and controllable in terms of safetyThe incidence of adverse events () related to the drug in the Carilli-beaded monoto-anti-group was only for the chemotherapy group (yes)In the research program, the study also fully considered the first-line treatment of the advanced stage of chinese esophageal squamous cancer, the use of yew alcohol treatment on the second-line chemotherapy control drugs on the selection of Dositase or Ilitikang more suitable for Chinese clinical practiceIn summary, experts said at the launch of the new edition of the guidelines that the study is a landmark study in immunotherapy for esophageal scale cancer in ChinaThe paboli bead sepsal recommendation (scale cancer s.class evidence) Paboli bead sepsis (scale cancer s class evidence) by the old version of the guide recommended "promoted" to grade expertrecommendation evidence level is also adjustedThe study confirmed that compared to standard chemotherapy pabolizumab, it significantly improved patients who had previously received a systematic treatment for metastatic esophageal cancerHowever, the study included both squamous and adenocarcinoma patients and only tested positive in patients with esophageal scale cancerTherefore, the adaptation certificate simply for patients with recurrent, locally advanced or metastatic esophageal scale cancer who have undergone first-line treatment and who have been positive (joint positive score:At the online press conference, experts pointed out that the relatively limited number of Chinese patients enrolled in the study of Paboli-Zhumonoinu in a later supplement of the Chinese extended queue only partly reflected its efficacy in patients with esophageal scale cancer in ChinaNavuli U-singofa recommendation (scale cancer evidence) Navuli u-singoffrom from the previous grade expert recommendation adjusted to the level of evidence recommended by experts from the previous level adjusted from the adjustmentIn the study, the treatment of patients with navulyo-e-supra-resistant patients with advanced esophageal syllprecedent reduced the risk of death by improving the median monthsExperts at the new guidelines release said that the number of patients in the group did not include chinese patients based on the previous mention of the differences between Chinese and other countries esophageal cancer patients, so whether Navuliu monotometreades can give Chinese patients the same benefits needs more data to confirm Gastric cancer triline immunotherapy update point Navuliu monoto-drug evidence grade recommendation (based on the study for period); phase study results: Navuliu monototherapy group for medium response time month long-lasting sustained remission time of up to months; Navuliu monosinoma rate significantly higher than placebo () treatment of gastric cancer patients better median for months; Navuli ue monosytic safety and good tolerance of adverse reactions associated with the incidence of only mild incidence Paboli zuma sedatives are suitable for patient-type evidence-level recommendation (based on research) for positive combined scores () The results: Paboli zuma suprem is used in the treatment of gastric esophagus adenocarcinoma () in advanced gastric cancer to reach the median monthly rate of disease control () Based on the above results, the U.S Food and Drug Administration () approved Paboli zuma to treat advanced or metastatic gastric or stomach cancers that are positive and advanced after previous treatment Bile tract tumor first-line treatment update key points: grade expert recommendation (class evidence) :() Dofeni () bepercentofad () combined with atilins () "" Donafini: Dajan Dafini's selection is based on the study is Donafini and Sorafeni head-to-head comparison relative to Solafenni Donafini more efficient low-toxic primary study median study results significantly better than Sorafini (months) "The first ice-breaking decade of the first-line pattern of liver cancer successfully extended and atali bead seone rebutlavitagain is anti-angiogenic drugs The joint "" programme was published at the Asian Congress of the European Society of Oncology and Internal Medicine (ECC) for the first time since Sorafeni's first success in the first place years ago The study included the random lysacized atarizumab or sorafenib in patients with advanced untreated treatment The main research endpoints include and The results showed that the median of the atali-bead singad and beva-bead-singtag groups significantly extended to a reduced risk of death () than the Solafeni group Another major study of endpoint aspects of atlizumab and bevalzumab combination therapy group for months and solafenib group for months () Grade expert recommendation (class evidence) :() Lunvalini joint Paboli bead singofa anti-Navoliu monotagated () chemotherapy combined carelli bead monotagated () apatini joint Carelli bead singofa second-line treatment update point: grade expert recommendation: () Carelli bead single single Anti-class evidence () apatinib evidence class expert recommendation (class evidence) :() Navuliu monoanti-mono-specific evidence Lofatinib joint anti-drug efficacy of the primary valatini joint Paboli bead sing-it-out breakthrough therapy has been identified as the joint program I Period research () at the meeting updated the latest data median up to months - median up to months to reach The annual meeting reported that the phase I study (study) of the lenfarinib joint navuliu monotonoids for non-resectionable patients was evaluated on the basis of criteria for the overall rate of clinical benefit (duration over the week) Preliminary data on first-line treatment of Carilli-beads monoantitherapy combined chemotherapy were satisfactory for patients with a single drug suprabutaor or protocol chemotherapy first-line treatment for advanced stage (hepatocellular carcinoma) or biliary tumors () in a national multicenter phase II study in the cohort The results showed that the confirmed median was the median month lyn the only cases () of patients who had not yet reached the disease progression A study published in the Journal of Clinical Oncology for apatinib combined carrified at adenocrezumab in the first line of treatment for advanced hepatocellular cancer () had a significant rate of efficacy in disease control to medium-on-the-disease-free progression () reaching a month-to-month disease control rate We can see that digestive tract tumors have updated many new programs and that most of the results of these new approaches are superior to traditional treatment sthets With the global new drugs in recent years, the hot research and development of the field of cancer can be said to usher in a lot of breakthroughs In addition to immuno-monodrug therapy, the joint domestic drug and immuno-targeted programme has also achieved bright results In addition, there are still a number of research being carried out around the world, including immuno-monodrug, immuno-targeting, immuno-local therapy, immunity and other worthy of expectation It is hoped that these studies will produce positive results at an early date and be approved clinically so that more patients can benefit from it   )